LS Investment Advisors LLC boosted its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 59.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,300 shares of the biotechnology company’s stock after acquiring an additional 3,479 shares during the quarter. LS Investment Advisors LLC’s holdings in Momenta Pharmaceuticals were worth $130,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in Momenta Pharmaceuticals by 12.0% during the 3rd quarter. Principal Financial Group Inc. now owns 606,700 shares of the biotechnology company’s stock valued at $11,224,000 after acquiring an additional 65,014 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Momenta Pharmaceuticals in the 3rd quarter worth $1,141,000. Candriam Luxembourg S.C.A. lifted its holdings in shares of Momenta Pharmaceuticals by 15.0% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 422,000 shares of the biotechnology company’s stock worth $7,807,000 after buying an additional 55,000 shares during the period. Fisher Asset Management LLC purchased a new stake in shares of Momenta Pharmaceuticals in the 3rd quarter worth $1,823,000. Finally, Sectoral Asset Management Inc lifted its holdings in shares of Momenta Pharmaceuticals by 24.4% in the 3rd quarter. Sectoral Asset Management Inc now owns 372,499 shares of the biotechnology company’s stock worth $6,891,000 after buying an additional 73,099 shares during the period. Institutional investors own 95.43% of the company’s stock.
Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) opened at $17.30 on Friday. The firm has a market capitalization of $1,320.00, a price-to-earnings ratio of -14.18 and a beta of 1.80. Momenta Pharmaceuticals, Inc. has a 12 month low of $11.85 and a 12 month high of $19.25.
MNTA has been the subject of several research reports. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. BidaskClub cut Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Stifel Nicolaus reiterated a “hold” rating and issued a $18.00 target price on shares of Momenta Pharmaceuticals in a report on Tuesday, January 30th. Cowen set a $15.00 target price on Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, November 1st. Finally, ValuEngine upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $15.33.
In related news, CEO Craig A. Wheeler sold 1,773 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $16.18, for a total transaction of $28,687.14. Following the completion of the sale, the chief executive officer now directly owns 258,713 shares in the company, valued at approximately $4,185,976.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Craig A. Wheeler sold 35,666 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $14.11, for a total value of $503,247.26. The disclosure for this sale can be found here. Insiders have sold a total of 112,002 shares of company stock valued at $1,733,746 over the last 90 days. 4.40% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) Position Boosted by LS Investment Advisors LLC” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.com-unik.info/2018/02/24/momenta-pharmaceuticals-inc-mnta-position-boosted-by-ls-investment-advisors-llc.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.